Source: Tech – South China Morning PostMainland China could become one of the first markets in the world to approve a drug fully designed by artificial intelligence, as advances in AI and human genetics combine to create a “seismic shift” in drug development, according to executives of pharmaceutical giants.
“We will see in 2026 that we move from AI-assisted discovery to fully AI-designed compounds, perhaps entering the pipeline,” said Marc Horn, president of Merck China, at the Asian Financial Forum on Tuesday in Hong Kong. “We…Read More